Related Experiment Videos
Alternative Payment Models and Diabetes Outcomes
1Section of General Internal Medicine, Department of Medicine, University of Chicago, 5841 S. Maryland Ave., MC2007, Chicago, IL, 60637, USA. mchin@bsd.uchicago.edu.
Current Diabetes Reports
|July 21, 2026
Summary
Alternative payment models (APMs) with shared savings or global budgets improve diabetes care and reduce costs. Effective APM design is crucial for success in population health management.
Area of Science:
- Health Services Research
- Diabetes Management
- Healthcare Policy
Background:
- Alternative Payment Models (APMs) are evolving healthcare payment strategies.
- Understanding their impact on chronic disease care, particularly diabetes, is critical.
Purpose of the Study:
- To determine the impact of APMs on diabetes care and outcomes.
- To explain APM principles and their role in population health.
- To provide a model for APM-supported diabetes care transformation.
Main Methods:
- Review of literature on APMs and diabetes care.
- Analysis of APM design features and their association with outcomes.
- Conceptual modeling of APM implementation for population health.
Main Results:
- Advanced APMs with shared savings or global budgets improved diabetes and chronic condition outcomes.
- These models reduced Medicare Part A and Part B costs.
- Accountability for total cost and quality of care is key for APMs.
Conclusions:
- Well-designed APMs can enhance diabetes care quality and reduce healthcare expenditures.
- Effective APM implementation requires a strategic mix of incentives, support, and risk.
- APMs support the shift towards evidence-based population health management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment: